Top

Published in:

Open Access 01-12-2022 | Myalgie | Research article

Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study

Authors: Pedro Augusto Sampaio Rocha-Filho, Pedro Mota Albuquerque, Larissa Clementino Leite Sá Carvalho, Mylana Dandara Pereira Gama, João Eudes Magalhães

Published in: The Journal of Headache and Pain | Issue 1/2022

Abstract

Background

Neurological symptoms are frequent among patients with COVID-19. Little is known regarding the repercussions of neurological symptoms for patients and how these symptoms are related to one another.

Objectives

To determine whether there is an association between the neurological symptoms in patients with COVID-19, and to characterize the headache.

Method

This was a cross-sectional study. All hospital inpatients and health workers at the Hospital Universitario Oswaldo Cruz with a PCR-confirmed COVID-19 infection between March and June 2020 were considered for the study and were interviewed by telephone at least 2-months after the acute phase of the disease. These patients were identified by the hospital epidemiological surveillance department. A semi-structured questionnaire was used containing sociodemographic and clinical data and the ID-Migraine.

Results

A total of 288 patients was interviewed; 53.1% were male; with a median age of 49.9 (41.5–60.5) years; 91.7% presented some neurological symptom; 22.2% reported some neurological symptom as the symptom that troubled them most during COVID-19. Neurological symptoms were: ageusia (69.8%), headache (69.1%), anosmia (67%), myalgia (44.4%), drowsiness (37.2%), agitation (20.8%); mental confusion (14.9%), syncope (4.9%) and epileptic seizures (2.8%). Females, those who presented with fever, sore throat, anosmia/ageusia and myalgia also presented significantly more with headache (logistic regression). The most frequent headache phenotype was a non-migraine phenotype, was of severe intensity and differed from previous headaches. This persisted for more than 30 days in 18% and for more than 90 days in 10% of patients. Thirteen percent of those with anosmia and 11% with ageusia continued with these complaints after more than 90 days of the acute phase of the disease. Aged over 50 years, agitation and epileptic seizures were significantly associated with mental confusion (logistic regression).

Conclusion

Headache is frequent in COVID-19, is associated with other symptoms such as fever, sore throat, anosmia, ageusia, and myalgia, and may persist beyond the acute phase of the disease.

Available only for authorised users

Nersesjan V, Amiri M, Lebech AM, Roed C, Mens H, Russell L, Fonsmark L, Berntsen M, Sigurdsson ST, Carlsen J, Langkilde AR, Martens P, Lund EL, Hansen K, Jespersen B, Folke MN, Meden P, Hejl AM, Wamberg C, Benros ME, Kondziella D (2021) Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. J Neurol 268(9):3086–3104. https://doi.org/10.1007/s00415-020-10380-xCrossRefPubMedPubMedCentral

Karadaş Ö, Öztürk B, Sonkaya AR (2020) A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurol Sci 41(8):1991–1995. https://doi.org/10.1007/s10072-020-04547-7CrossRefPubMedPubMedCentral

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol e201127:2020.02.22.20026500 77(6):683–690. https://doi.org/10.1001/jamaneurol.2020.1127CrossRefPubMed

Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, Koralnik IJ (2020) Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol 7(11):2221–2230. https://doi.org/10.1002/acn3.51210CrossRefPubMedPubMedCentral

Koh JS, De Silva DA, Quek AML et al (2020) Neurology of COVID-19 in Singapore. J Neurol Sci 418:117118. https://doi.org/10.1016/j.jns.2020.117118CrossRefPubMedPubMedCentral

Boldrini M, Canoll PD, Klein RS (2021) How COVID-19 affects the brain. JAMA Psychiatry 78(6):682–683. https://doi.org/10.1001/jamapsychiatry.2021.0500CrossRefPubMed

Amanat M, Rezaei N, Roozbeh M, Shojaei M, Tafakhori A, Zoghi A, Darazam IA, Salehi M, Karimialavijeh E, Lima BS, Garakani A, Vaccaro A, Ramezani M (2021) Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurol 21(1):116. https://doi.org/10.1186/s12883-021-02152-5CrossRefPubMedPubMedCentral

Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, Ora J, Mina GG, Puxeddu E, Balbi O, Pezzuto G, Magrini A, Rogliani P, Andreoni M, Mercuri NB (2020) Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun 88:11–16. https://doi.org/10.1016/j.bbi.2020.05.037CrossRefPubMedPubMedCentral

Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, González E, Redondo-Peñas I, Perona-Moratalla AB, del Valle-Pérez JA, Gracia-Gil J, Rojas-Bartolomé L, Feria-Vilar I, Monteagudo M, Palao M, Palazón-García E, Alcahut-Rodríguez C, Sopelana-Garay D, Moreno Y, Ahmad J, Segura T (2020) Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 95(8):e1060–e1070. https://doi.org/10.1212/WNL.0000000000009937CrossRefPubMedPubMedCentral

10.

Pinna P, Grewal P, Hall JP, Tavarez T, Dafer RM, Garg R, Osteraas ND, Pellack DR, Asthana A, Fegan K, Patel V, Conners JJ, John S, Silva ID (2020) Neurological manifestations and COVID-19: experiences from a tertiary care center at the frontline. J Neurol Sci 415:116969. https://doi.org/10.1016/j.jns.2020.116969CrossRefPubMedPubMedCentral

11.

Pinzon RT, Wijaya VO, Buana RB, al Jody A, Nunsio PN (2020) Neurologic characteristics in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Front Neurol 11:565. https://doi.org/10.3389/fneur.2020.00565CrossRefPubMedPubMedCentral

12.

Trigo J, García-Azorín D, Planchuelo-Gómez Á, Martínez-Pías E, Talavera B, Hernández-Pérez I, Valle-Peñacoba G, Simón-Campo P, de Lera M, Chavarría-Miranda A, López-Sanz C, Gutiérrez-Sánchez M, Martínez-Velasco E, Pedraza M, Sierra Á, Gómez-Vicente B, Arenillas JF, Guerrero ÁL (2020) Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study. J Headache Pain 21(1):94. https://doi.org/10.1186/s10194-020-01165-8CrossRefPubMedPubMedCentral

13.

Rocha-Filho PAS, Magalhães JE (2020) Headache associated with COVID-19: frequency, characteristics and association with anosmia and ageusia. Cephalalgia 40(13):1443–1451. https://doi.org/10.1177/0333102420966770CrossRefPubMedPubMedCentral

14.

Membrilla JA, de Lorenzo Í, Sastre M, Díaz de Terán J (2020) Headache as a cardinal symptom of coronavirus disease 2019: a cross-sectional study. Headache 60(10):2176–2191. https://doi.org/10.1111/head.13967CrossRefPubMed

15.

Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, Simón-Campo P, de Lera M, Chavarría-Miranda A, López-Sanz C, Gutiérrez-Sánchez M, Martínez-Velasco E, Pedraza M, Sierra Á, Gómez-Vicente B, Guerrero Á, Arenillas JF (2020) Anosmia is associated with lower in-hospital mortality in COVID-19. J Neurol Sci 419:117163. https://doi.org/10.1016/j.jns.2020.117163CrossRefPubMedPubMedCentral

16.

Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, Razani B, Mwangi J, Asadi-Pooya AA, Malekmakan L, Bastani B (2021) Long COVID, a comprehensive systematic scoping review. Infection 49(6):1–24. https://doi.org/10.1007/s15010-021-01666-xCrossRef

17.

de Mattos ACMT, de Souza JA, Moreira Filho PF et al (2017) ID-migraine™ questionnaire and accurate diagnosis of migraine. Arq Neuropsiquiatr 75(7):446–450. https://doi.org/10.1590/0004-282X20170069CrossRefPubMed

18.

López JT, García-Azorín D, Planchuelo-Gómez Á et al (2020) Phenotypic characterization of acute headache attributed to SARS-CoV-2: an ICHD-3 validation study on 106 hospitalized patients. Cephalalgia 40(13):1432–1442. https://doi.org/10.1177/0333102420965146CrossRefPubMedPubMedCentral

19.

García-Azorín D, Sierra Á, Trigo J, Alberdi A, Blanco M, Calcerrada I, Cornejo A, Cubero M, Gil A, García-Iglesias C, Lozano AG, Martínez Badillo C, Montilla C, Mora M, Núñez G, Paniagua M, Pérez C, Rojas M, Ruiz M, Sierra L, Hurtado ML, Guerrero Peral ÁL (2021) Frequency and phenotype of headache in covid-19: a study of 2194 patients. Sci Rep 11(1):14674. https://doi.org/10.1038/s41598-021-94220-6CrossRefPubMedPubMedCentral

20.

Fernández-de-las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, Cuadrado ML, García-Azorín D, Arendt-Nielsen L, Plaza-Manzano G (2021) Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol 28(11):3820–3825. https://doi.org/10.1111/ene.15040CrossRefPubMed

21.

Caronna E, Ballvé A, Llauradó A, Gallardo VJ, Ariton DM, Lallana S, López Maza S, Olivé Gadea M, Quibus L, Restrepo JL, Rodrigo-Gisbert M, Vilaseca A, Hernandez Gonzalez M, Martinez Gallo M, Alpuente A, Torres-Ferrus M, Pujol Borrell R, Alvarez-Sabin J, Pozo-Rosich P (2020) Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia 40(13):1410–1421. https://doi.org/10.1177/0333102420965157CrossRefPubMedPubMedCentral

22.

Hussein M, Fathy W, Eid RA, Abdel-Hamid HM, Yehia A, Sheemy MS, Ragaie C, Dahshan A, Rizk HI, laz N, Magdy R (2021) Relative frequency and risk factors of COVID-19 related headache in a sample of egyptian population: a hospital-based study. Pain Med (United States) 22(9):2092–2099. https://doi.org/10.1093/pm/pnab020CrossRef

23.

Poncet-Megemont L, Paris P, Tronchere A, Salazard JP, Pereira B, Dallel R, Aumeran C, Beytout J, Jacomet C, Laurichesse H, Lesens O, Mrozek N, Vidal M, Moisset X (2020) High prevalence of headaches during Covid-19 infection: a retrospective cohort study. Headache 60(10):2578–2582. https://doi.org/10.1111/head.13923CrossRefPubMed

24.

García-Azorín D, Trigo J, Talavera B, Martínez-Pías E, Sierra Á, Porta-Etessam J, Arenillas JF, Guerrero ÁL (2020) Frequency and type of red flags in patients with Covid-19 and headache: a series of 104 hospitalized patients. Headache 60(8):1664–1672. https://doi.org/10.1111/head.13927CrossRefPubMed

25.

Gonzalez-Martinez A, Fanjul V, Ramos C, Serrano Ballesteros J, Bustamante M, Villa Martí A, Álvarez C, García del Álamo Y, Vivancos J, Gago-Veiga AB (2021) Headache during SARS-CoV-2 infection as an early symptom associated with a more benign course of disease: a case–control study. Eur J Neurol 28(10):3426–3436. https://doi.org/10.1111/ene.14718CrossRefPubMed

26.

Karadaş Ö, Öztürk B, Sonkaya AR, Taşdelen B, Özge A, Bolay H (2021) Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6. Neurol Sci 42(5):1665–1673. https://doi.org/10.1007/s10072-020-04978-2CrossRefPubMedPubMedCentral

27.

Planchuelo-Gómez Á, Trigo J, de Luis-García R, Guerrero ÁL, Porta-Etessam J, García-Azorín D (2020) Deep phenotyping of headache in hospitalized COVID-19 patients via principal component analysis. Front Neurol 11:583870. https://doi.org/10.3389/fneur.2020.583870CrossRefPubMedPubMedCentral

28.

Bolay H, Karadas Ö, Oztürk B, Sonkaya R, Tasdelen B, Bulut TDS, Gülbahar Ö, Özge A, Baykan B (2021) HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism. J Headache Pain 22(1):94. https://doi.org/10.1186/s10194-021-01306-7CrossRefPubMedPubMedCentral

29.

Trigo J, García-Azorín D, Sierra-Mencía Á, Tamayo-Velasco Á, Martínez-Paz P, Tamayo E, Guerrero AL, Gonzalo-Benito H (2021) Cytokine and interleukin profile in patients with headache and COVID-19: a pilot, CASE-control, study on 104 patients. J Headache Pain 22(1):51. https://doi.org/10.1186/s10194-021-01268-wCrossRefPubMedPubMedCentral

30.

Magdy R, Hussein M, Ragaie C, Abdel-Hamid HM, Khallaf A, Rizk HI, Dahshan A (2020) Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: a cross sectional study. Cephalalgia 40(13):1422–1431. https://doi.org/10.1177/0333102420965140CrossRefPubMedPubMedCentral

31.

Vacchiano V, Riguzzi P, Volpi L, Tappatà M, Avoni P, Rizzo G, Guerra L, Zaccaroni S, Cortelli P, Michelucci R, Liguori R (2020) Early neurological manifestations of hospitalized COVID-19 patients. Neurol Sci 41(8):2029–2031. https://doi.org/10.1007/s10072-020-04525-zCrossRefPubMedPubMedCentral

32.

Sampaio Rocha-Filho PA, Voss L (2020) Persistent headache and persistent anosmia associated with COVID-19. Headache 60(8):1797–1799. https://doi.org/10.1111/head.13941CrossRefPubMed

33.

Al-Hashel JY, Abokalawa F, Alenzi M et al (2021) Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study. J Headache Pain 22(1):97. https://doi.org/10.1186/s10194-021-01314-7CrossRefPubMedPubMedCentral

34.

Martelletti P, Bentivegna E, Luciani M, Spuntarelli V (2020) Headache as a prognostic factor for COVID-19. Time to re-evaluate. SN Compr Clin Med 2(12):2509–2510. https://doi.org/10.1007/s42399-020-00657-7CrossRefPubMedPubMedCentral

35.

Martelletti P, Bentivegna E, Spuntarelli V, Luciani M (2021) Long-COVID headache. SN Compr Clin Med 3(8):1704–1706. https://doi.org/10.1007/s42399-021-00964-7CrossRefPubMedPubMedCentral

36.

Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T (2020) The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and Meta-analysis. Otolaryngol - Head Neck Surg (United States) 163(1):3–11. https://doi.org/10.1177/0194599820926473CrossRef

37.

Saniasiaya J, Islam MA, Abdullah B (2021) Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): a Meta-analysis of 27,492 patients. Laryngoscope 131(4):865–878. https://doi.org/10.1002/lary.29286CrossRefPubMed

38.

Siddiqi HK, Mehra MR (2020) COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Hear Lung Transplant 39(5):405–407. https://doi.org/10.1016/j.healun.2020.03.012CrossRef

39.

Lippi G, Sanchis-Gomar F, Henry BM (2020) COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon. Ann Transl Med 8:693–693. https://doi.org/10.21037/atm-20-3989CrossRefPubMedPubMedCentral

40.

Barrantes FJ (2021) The unfolding palette of COVID-19 multisystemic syndrome and its neurological manifestations. Brain Behav Immun-Heal 14:100251. https://doi.org/10.1016/j.bbih.2021.100251CrossRef

41.

Lechien JR, Chiesa-Estomba CM, De Siati DR et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol 277(8):2251–2261. https://doi.org/10.1007/s00405-020-05965-1CrossRef

42.

Porta-Etessam J, Matías-Guiu JA, González-García N, Gómez Iglesias P, Santos-Bueso E, Arriola-Villalobos P, García-Azorín D, Matías-Guiu J (2020) Spectrum of headaches associated with SARS-CoV-2 infection: study of healthcare professionals. Headache 60(8):1697–1704. https://doi.org/10.1111/head.13902CrossRefPubMed

43.

Aragão MFVV, de Carvalho Leal M, Queiroga Cartaxo Filho O et al (2020) Anosmia in COVID-19 associated with injury to the olfactory bulbs evident on MRI. Am J Neuroradiol 41:1703–1706. https://doi.org/10.3174/ajnr.a6675CrossRefPubMedPubMedCentral

44.

Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M, Meziani F (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382(23):2268–2270. https://doi.org/10.1056/nejmc2008597CrossRefPubMed

45.

Rebora P, Rozzini R, Bianchetti A, Blangiardo P, Marchegiani A, Piazzoli A, Mazzeo F, Cesaroni G, Chizzoli A, Guerini F, Bonfanti P, Morandi A, Faraci B, Gentile S, Bna C, Savelli G, Citerio G, Valsecchi MG, Mazzola P, Bellelli G, for the CoViD‐19 Lombardia Team (2021) Delirium in patients with SARS-CoV-2 infection: a multicenter study. J Am Geriatr Soc 69(2):293–299. https://doi.org/10.1111/jgs.16969CrossRefPubMed

Title: Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study
Authors: Pedro Augusto Sampaio Rocha-Filho
Pedro Mota Albuquerque
Larissa Clementino Leite Sá Carvalho
Mylana Dandara Pereira Gama
João Eudes Magalhães
Publication date: 01-12-2022
Publisher: Springer Milan
Keywords: Myalgie
Myalgia
Confusion
COVID-19
Sore Throat
Agitation
Headache
Anosmia
Published in: The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-021-01367-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study

Abstract

Background

Objectives

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials

Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients

Correction to: Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists

Trends in utilization and costs of migraine medications, 2017–2020

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients